CN108864149B - 雷帕霉素衍生物的纯化 - Google Patents

雷帕霉素衍生物的纯化 Download PDF

Info

Publication number
CN108864149B
CN108864149B CN201811056060.XA CN201811056060A CN108864149B CN 108864149 B CN108864149 B CN 108864149B CN 201811056060 A CN201811056060 A CN 201811056060A CN 108864149 B CN108864149 B CN 108864149B
Authority
CN
China
Prior art keywords
compound
solvent
mixture
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811056060.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108864149A (zh
Inventor
M·W·卡约
R·S·福尼科拉
I·科瓦奇克
L·康达维提
A·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosensors International Group Ltd
Original Assignee
Biosensors International Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosensors International Group Ltd filed Critical Biosensors International Group Ltd
Publication of CN108864149A publication Critical patent/CN108864149A/zh
Application granted granted Critical
Publication of CN108864149B publication Critical patent/CN108864149B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201811056060.XA 2013-03-15 2014-03-17 雷帕霉素衍生物的纯化 Active CN108864149B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361799857P 2013-03-15 2013-03-15
US61/799,857 2013-03-15
PCT/US2014/030602 WO2014145780A1 (en) 2013-03-15 2014-03-17 Purification of rapamycin derivatives
CN201480013252.6A CN105102967B (zh) 2013-03-15 2014-03-17 雷帕霉素衍生物的纯化

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480013252.6A Division CN105102967B (zh) 2013-03-15 2014-03-17 雷帕霉素衍生物的纯化

Publications (2)

Publication Number Publication Date
CN108864149A CN108864149A (zh) 2018-11-23
CN108864149B true CN108864149B (zh) 2022-04-05

Family

ID=51538094

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811056060.XA Active CN108864149B (zh) 2013-03-15 2014-03-17 雷帕霉素衍生物的纯化
CN201480013252.6A Active CN105102967B (zh) 2013-03-15 2014-03-17 雷帕霉素衍生物的纯化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480013252.6A Active CN105102967B (zh) 2013-03-15 2014-03-17 雷帕霉素衍生物的纯化

Country Status (8)

Country Link
US (5) US9598439B2 (enExample)
EP (1) EP2972258B1 (enExample)
JP (4) JP2016519086A (enExample)
CN (2) CN108864149B (enExample)
CA (1) CA2901162C (enExample)
ES (1) ES2897473T3 (enExample)
SG (3) SG11201507406YA (enExample)
WO (1) WO2014145780A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934401C (en) 2009-11-02 2017-01-10 Pulse Therapeutics, Inc. Magnetomotive stator system and methods for wireless control of magnetic rotors
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
CN116102576B (zh) * 2021-11-09 2025-08-29 上海博畅医疗科技有限公司 一种优美莫司晶体的制造方法及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
CN101077334A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 含酪氨酸激酶抑制剂的抗癌组合物
CN101522691A (zh) * 2006-11-27 2009-09-02 泰尔茂株式会社 O-烷基化雷帕霉素衍生物的制备方法及o-烷基化雷帕霉素衍生物
TW200948361A (en) * 2008-05-26 2009-12-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Method for synthesizing Biolimus A9 and the like and method for improving stability of the same
CN102464669A (zh) * 2010-11-17 2012-05-23 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
KR20050114262A (ko) * 2003-03-31 2005-12-05 테바 기오기스제르갸르 레스즈베니타르사사그 마크로라이드의 결정화 및 정제
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
CA2548297C (en) * 2003-12-05 2011-06-14 Biocon Limited Process for the purification of macrolides
JP4716280B2 (ja) * 2004-03-01 2011-07-06 テルモ株式会社 Ｏ−アルキル化ラパマイシン誘導体の製造法
KR20070015544A (ko) * 2004-04-14 2007-02-05 와이어쓰 라파마이신 42-에스테르 유도체의 위치특이성 합성
WO2006060615A1 (en) 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Non-hygroscopic and powdery amorphous pimecrolimus
AU2006218918A1 (en) * 2005-03-02 2006-09-08 Wyeth Purification of rapamycin
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
CA2644156A1 (en) 2006-03-07 2007-09-13 Wyeth Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
BRPI0621967A2 (pt) * 2006-11-10 2011-12-27 Biocon Ltd forma pura de rapamicina e um processo para recuperaÇço e purificaÇço da mesma
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
US20100055145A1 (en) * 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
EP2421571A2 (en) 2009-04-24 2012-02-29 Boston Scientific Scimed, Inc. Use of drug polymorphs to achieve controlled drug delivery from a coated medical device
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222627A1 (en) * 2005-03-30 2006-10-05 Andrew Carter Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue
CN101522691A (zh) * 2006-11-27 2009-09-02 泰尔茂株式会社 O-烷基化雷帕霉素衍生物的制备方法及o-烷基化雷帕霉素衍生物
CN101077334A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 含酪氨酸激酶抑制剂的抗癌组合物
TW200948361A (en) * 2008-05-26 2009-12-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Method for synthesizing Biolimus A9 and the like and method for improving stability of the same
CN102464669A (zh) * 2010-11-17 2012-05-23 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法

Also Published As

Publication number Publication date
US20200270272A1 (en) 2020-08-27
EP2972258A4 (en) 2016-12-21
SG10202112135VA (en) 2021-12-30
JP2021121601A (ja) 2021-08-26
WO2014145780A1 (en) 2014-09-18
JP2023164476A (ja) 2023-11-10
JP2019089848A (ja) 2019-06-13
CA2901162C (en) 2021-06-01
US20160002262A1 (en) 2016-01-07
ES2897473T3 (es) 2022-03-01
US10597406B2 (en) 2020-03-24
CN108864149A (zh) 2018-11-23
WO2014145780A4 (en) 2014-11-20
US9598439B2 (en) 2017-03-21
SG11201507406YA (en) 2015-10-29
US11046711B2 (en) 2021-06-29
US10202402B2 (en) 2019-02-12
CA2901162A1 (en) 2014-09-18
CN105102967B (zh) 2018-10-12
JP2016519086A (ja) 2016-06-30
EP2972258A1 (en) 2016-01-20
HK1218959A1 (zh) 2017-03-17
US11780850B2 (en) 2023-10-10
EP2972258B1 (en) 2021-08-04
US20190256527A1 (en) 2019-08-22
CN105102967A (zh) 2015-11-25
US20220024947A1 (en) 2022-01-27
US20170334928A1 (en) 2017-11-23
SG10201707632PA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
US11780850B2 (en) Purification of rapamycin derivatives using temperature induced phase separation
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
AU2007209569B2 (en) Process for the preparation of rapamycin derivatives
CA3072601A1 (en) Polymorphs and co-crystals of roxadustat
US9434744B2 (en) Low temperature synthesis of rapamycin derivatives
CN121605107A (zh) 2-[(3r)-2-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧杂环丁烷-3-基)哌嗪-1-基]-戊-2-烯腈及其溶剂化物形式的制备方法
HK1218959B (en) Purification of rapamycin derivatives
CN109641934B (zh) 胆酸衍生物游离碱，晶型及其制备方法和应用
EA015940B1 (ru) Способ получения кристаллических форм орлистата
CN110741006B (zh) 将粗子囊霉素转化为纯化的吡美莫司的方法
CN108659037B (zh) 丙戊酸磷脂衍生物的多晶型物及制备方法
Zhigileva et al. Examination of Diels–Alder/Tsuji–Trost Route towards Kopsia Alkaloids
HK1218118B (en) Low temperature synthesis of rapamycin derivatives
AU2011254079A1 (en) Process for the preparation of rapamycin derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant